mardi 25 octobre 2016

Onco Actu du 25 octobre 2016

1. Biologie

Promising drug target for aggressive ‘triple-negative’ breast cancers identified [The Institute of Cancer Research]

Genetic hallmarks of acute lymphoblastic leukemia subtype uncovered [St. Jude Children's Research Hospital]

DINO RNA Molecule Triggers Anticancer Response in Damaged Cells [NCI]

2.10 Etiologie - Alcool

Women are fast catching up to men in alcohol consumption — and abuse [STAT]

Women now drink as much alcohol as men, global study finds [The Guardian]

Women catching up with men in alcohol consumption and its associated harms [BMJ]

3.1 Tabac

One-fourth of US cancer deaths linked with one thing: smoking [STAT]

Burden of cancer deaths from smoking heaviest in U.S. south [Reuters]

3.3 Prévention - Vaccins

Retracted paper linking HPV vaccine to behavioral issues republished after revisions [Retraction Watch]

4. Dépistage, diagnostic et pronostic

Study suggests link between bacterium and oesophageal cancer survival [Cancer Research UK]

Presence of Certain Oral Bacterium in Esophageal Cancer Samples Associated With Shorter Patient Survival [AACR]

4.10 Dép., diag. & prono. - FDA, EMA, NICE,...

Philips seeks expanded approval for digital cancer tool [PharmaForum]

4.10 Dép., diag. & prono. - Poumon

Identification of new subtypes of lung cancer can lead to personalized therapies with better outcomes [Baylor College of Medicine]

4.5 Dép., diag. & prono. - Colorectal

A Noninvasive Colon Cancer Test That's FIT To Be Tried [NPR]

4.9 Dép., diag. & prono. - Sein

A key to unlocking the mystery of triple negative breast [McGill University]

5.12 Immunothérapies

Fighting cancer with the power of immunity [MIT News]

Modified Immunotherapy Approach Shows Promise for Leukemia [NCI]

5.12.2 Immunothérapies - CAR-T

Novartis promises a speedy CAR-T pitch, but questions linger in wake of restructuring [EndPoints]

5.2 Pharma

Oasmia buys estrogen receptor cancer drug, raises cash [FierceBiotech]

New Listeria fears spotlighted as Aduro’s CRS-207 is slapped with partial hold [EndPoints]

5.3 Traitements - FDA, EMA, NICE...

How to make better use of patient registries to collect high-quality data on medicines [EMA]

5.3.4 Traitements - AMM (FDA, EMA)

Merck's Keytruda wins coveted first-line lung cancer nod, cementing rise 'from laggard to leader' [FiercePharma]

FDA: Keytruda Now OK For Some Patients With Untreated Lung Cancer [Xconomy]

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Metastatic NSCLC for First-Line Treatment of Patients Whose Tumors Have High PD-L1 Expression (Tumor Proportion Score [TPS] of 50 Percent or More) With No EGFR or ALK Genomic Tumor Aberrations [Merck]

Why wait? FDA gives early OK to Merck’s Keytruda for frontline lung cancer [EndPoints]

FDA approves Merck's lung cancer drug as first-line treatment [Reuters]

6.4 Médico-éco

Radiotherapy gets the investment it needs [Cancer Research UK]

NHS to spend £130m upgrading or replacing radiotherapy machines [The Guardian]

6.5 Médecines alternatives

German alternative cancer clinics: Combining experimental therapeutics with rank quackery and charging big bucks for it [Science-Based Medicine]

6.6 Publications

7 signs a scientific paper’s authorship was bought [Retraction Watch]